Investigational reverse transcriptase inhibitors for the treatment of HIV

Bibliography

• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. Available from: http://aidsinfo.Nih.Gov/contentfiles/lvguidelines/adultandadolescentgl.Pdf [Accessed 6 March 2015]
   Google Scholar
• Rothenberger MK, Keele BF, Wietgrefe SW, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA 2015;112(10):1126-34
   PubMed Web of Science ®Google Scholar
• Guo D, Zhang G, Wysocki TA, et al. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J Virol 2014;88(17):9504-13
   PubMed Web of Science ®Google Scholar
• Kanmogne GD, Singh S, Roy U, et al. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine 2012;7:2373-88
   PubMed Web of Science ®Google Scholar
• Roy U, McMillan J, Alnouti Y, et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis 2012;206(10):1577-88
   PubMed Web of Science ®Google Scholar
• Chowers M, Gottesman BS, Leibovici L, et al. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: Systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2010;29(7):779-86
   PubMed Web of Science ®Google Scholar
• Kumar S RP, Earla R, Kumar A. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol 2015;11(3):343-55
   PubMed Web of Science ®Google Scholar
• Rao PSS CT, Kumar S. New antiretroviral therapies and potential drug interactions in HIV-infected drug abusers. Journal of Antivirals & Antiretrovirals 2015;6:86-91
   Google Scholar
• Chattopadhyay K, Aldous C. A brief review on human mtdna mutations and NRTI-associated mtDNA toxicity and mutations. Mitochondrial DNA 2014;1-3. [Epub ahead of print]
   PubMedGoogle Scholar
• Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10(1):26-39
   PubMedGoogle Scholar
• Flexner C, Saag M. The antiretroviral drug pipeline: Prospects and implications for future treatment research. Curr Opin HIV AIDS 2013;8(6):572-8
   PubMed Web of Science ®Google Scholar
• Haraguchi K, Takeda S, Kubota Y, et al. From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4’-ethynylstavudine-festinavir. Curr Pharm Des 2013;19(10):1880-97
   PubMed Web of Science ®Google Scholar
• Cotte L, Dellamonica P, Raffi F, et al. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. J Acquir Immune Defic Syndr 2013;63(3):346-54
   PubMed Web of Science ®Google Scholar
• Li Z, Terry B, Olds W, et al. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations. Antimicrob Agents Chemother 2013;57(11):5500-8
   PubMed Web of Science ®Google Scholar
• Lanier ER, Ptak RG, Lampert BM, et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother 2010;54(7):2901-9
   PubMed Web of Science ®Google Scholar
• Cory TJ, Schacker TW, Stevenson M, et al. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS 2013;8(3):190-5
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013;63(4):449-55
   PubMed Web of Science ®Google Scholar
• Bam RA, Birkus G, Babusis D, et al. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors. Antivir Ther 2014;19(7):669-77
   PubMed Web of Science ®Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother 2014;69(5):1362-9
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439-48
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004;2(4):323-32
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65(3):445-8
   PubMed Web of Science ®Google Scholar
• Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013;21(1):6-14
   PubMedGoogle Scholar
• Lai MT, Feng MZ, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2014;58(3):1652-63
   PubMed Web of Science ®Google Scholar
• Feng M, Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 2015;59(1):590-8
   PubMed Web of Science ®Google Scholar
• Cote B, Burch JD, Asante-Appiah E, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett 2014;24(3):917-22
   PubMed Web of Science ®Google Scholar
• Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc 2014;17(4 Suppl 3):28
   Google Scholar
• Cha YJ, Lim KS, Park MK, et al. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse-transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther 2014;8:1613-19
   PubMed Web of Science ®Google Scholar
• Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: Initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37(2):178-82
   PubMed Web of Science ®Google Scholar
• Mowbray CE, Burt C, Corbau R, et al. Pyrazole nnrtis 4: Selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett 2009;19(20):5857-60
   PubMed Web of Science ®Google Scholar
• Corbau R, Mori J, Phillips C, et al. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2010;54(10):4451-63
   PubMed Web of Science ®Google Scholar
• Davis J, Hackman F, Ndongo MN, et al. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, phase I clinical study in healthy male volunteers. Clin Ther 2010;32(11):1889-95
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Langdon G, LaBadie RR, et al. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Antimicrob Agents Chemother 2012;56(2):887-92
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Langdon G, Layton G, et al. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects. J Acquir Immune Defic Syndr 2012;60(1):24-32
   PubMed Web of Science ®Google Scholar
• Vernazza P, Wang C, Pozniak A, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr 2013;62(2):171-9
   PubMed Web of Science ®Google Scholar
• Sun LQ, Zhu L, Qian KD, et al. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem 2012;55(16):7219-29
   PubMed Web of Science ®Google Scholar
• Arien KK, Venkatraj M, Michiels J, et al. Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. J Antimicrob Chemother 2013;68(9):2038-47
   PubMed Web of Science ®Google Scholar
• Grammen C, Arien KK, Venkatraj M, et al. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Res 2014;101:113-21
   PubMed Web of Science ®Google Scholar
• Xu Z, Ba M, Zhou H, et al. 2,4,5-trisubstituted thiazole derivatives: A novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase. Eur J Med Chem 2014;85:27-42
   PubMed Web of Science ®Google Scholar
• Kim TH, Ko Y, Christophe T, et al. Identification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assay. PLoS ONE 2013;8(7):e68767
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
   PubMed Web of Science ®Google Scholar
• Nachega JB, Parienti J, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 2014;58(9):1297-307
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel. JAMA 2012;308(4):387-402
   PubMed Web of Science ®Google Scholar
• Writing G, Williams I, Churchill D, et al. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated november 2013.). HIV med 2014;15(Suppl 1):1-85
   Google Scholar
• Gupta SK, Nutan N. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV AIDS (Auckl) 2013;5:295-307
   Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74
   PubMed Web of Science ®Google Scholar
• Facts 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. 2015. Available from: http://www.croiconference.org/sessions/facts-001-phase-iii-trial-pericoital-tenofovir-1-gel-hiv-prevention-women
   Google Scholar
• MTN statement on decision to discontinue use of tenofovir gel in voice, a major hiv prevention study in women. microbicide trials network. Available from: http://www.mtnstopshiv.org/node/3909
   Google Scholar
• Caprisa 008. Available from: http://www.avac.org/caprisa-008
   Google Scholar
• Akil A, Parniak MA, Dezzutti CS, et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res 2011;1(3):209-22
   PubMed Web of Science ®Google Scholar
• Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26(11):1181-90
   PubMed Web of Science ®Google Scholar
• Rosenberg ZF, Devlin B. Future strategies in microbicide development. Best Pract Res Clin Obstet Gynaecol 2012;26(4):503-13
   PubMed Web of Science ®Google Scholar
• Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2012;28(11):1412-21
   PubMed Web of Science ®Google Scholar
• McGowan I, Hoesley C, Cranston RD, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (mtn-007). PLoS ONE 2013;8(4):e60147
   Google Scholar
• Spreen WR, Margolis DA, Pottage JC. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013;8(6):565-71
   PubMed Web of Science ®Google Scholar
• Puligujja P, McMillan J, Kendrick L, et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine 2013;9(8):1263-73
   PubMed Web of Science ®Google Scholar
• Ramana LN, Sharma S, Sethuraman S, et al. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. Biochim Biophys Acta 2014;1840(1):476-84
   PubMed Web of Science ®Google Scholar
• Archin NM, Espeseth A, Parker D, et al. Expression of latent hiv induced by the potent hdac inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009;25(2):207-12
   PubMed Web of Science ®Google Scholar
• Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS 2014;28(10):1479-87
   PubMed Web of Science ®Google Scholar
• Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009;51(4):416-23
   PubMed Web of Science ®Google Scholar
• Jayant RD, Atluri VSr, Agudelo M, et al. Sustained-release nanoart formulation for the treatment of neuroAIDS. Int J Nanomedicine 2015;10:1077-93
   PubMed Web of Science ®Google Scholar
• Nowacek AS, McMillan J, Miller R, et al. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: Implications for neuroaids therapeutics. J Neuroimmune Pharmacol 2010;5(4):592-601
   PubMed Web of Science ®Google Scholar
• Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3(112):112-14
   Web of Science ®Google Scholar
• Pilakka-Kanthikeel S, Atluri VS, Sagar V, et al. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: An in-vitro study. PLoS One 2013;8(4):e62241
   PubMed Web of Science ®Google Scholar
• Sagar V, Pilakka-Kanthikeel S, Pottathil R, et al. Towards nanomedicines for neuroAIDS. Rev Med Virol 2014;24(2):103-24
   PubMed Web of Science ®Google Scholar